Evidence map›Paper›PMID 41048431›Full record

ArticleFrontiers in endocrinology2025

Future horizons in diabetes treatment: hypoglycemic activity of [1,2,4]triazino[2,3-

Serhii Trzhetsynskyi, Inna Nosulenko, Anna Kinichenko, Dmytro Skoryna, Halyna Berest, Volodymyr Shvets, Oleksii Voskoboinik, Serhii Kovalenko, Pavlo Petakh, Oleksandr Kamyshnyi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Serhii TrzhetsynskyiDepartment of Pharmacognosy, Pharmacology and Botany, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia, Ukraine.
Inna NosulenkoDepartment of Pharmacognosy, Pharmacology and Botany, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia, Ukraine.
Anna KinichenkoDepartment of Pharmacognosy, Pharmacology and Botany, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia, Ukraine.
Dmytro SkorynaDepartment of Pharmaceutical, Organic and Bioorganic Chemistry, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia, Ukraine.
Halyna BerestDepartment of Clinical Pharmacy, Pharmacotherapy, Pharmacognosy and Pharmaceutical Chemistry, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia, Ukraine.
Volodymyr ShvetsDepartment of Biological Chemistry, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia, Ukraine.
Oleksii VoskoboinikDepartment of Composite Materials, Chemistry and Technologies, National University "Zaporizhzhia Polytechnic", Zaporizhzhia, Ukraine.
Serhii KovalenkoResearch Institute of Chemistry and Geology, Oles Honchar Dnipro National University, Dnipro, Ukraine.
Pavlo PetakhDepartment of Biochemistry and Pharmacology, Uzhhorod National University, Uzhhorod, Ukraine.
Oleksandr KamyshnyiDepartment of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus (T2DM) remains a significant and multifaceted challenge for modern healthcare. This issue becomes even more pressing during times of armed conflict and the subsequent recovery period, as research indicates an increased incidence of T2DM among combat veterans, largely due to post-traumatic stress disorder. Although numerous antidiabetic drugs are currently available, achieving optimal control of hyperglycemia continues to be problematic. In this context, and as part of a focused search for biologically active substances within the class of substituted and condensed [1,2,4]triazino[2,3-

Indexed as

Diabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Hypoglycemic AgentsQuinazolinesAnimalsBlood GlucoseGlucose Tolerance TestMaleRatsRats, WistarBlood GlucoseHypoglycemic AgentsQuinazolines[1,2,4]triazino[2,3-c]quinazolinesdiabetes mellitushypoglycemic activityinsulin resistancemolecular docking

Identifiers

PMID41048431
PMCPMC12488427

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.